fda stop tirzepatide Announced Removal of from the Drug Shortage List FDA Announces End To Compounded

Dosing Considerations and MHRA Safety Guidance In clinical trials, retatrutide was administered via weekly subcutaneous injection at escalating doses of 112 mg, but the MHRA has issued no prescribing guidance and warns against its use outside approved trial settings

Wegovy received UK marketing authorisation in 2023, and NICE guidance (TA875) supports its use within the NHS for adults with a BMI of at least 35 kg/m (or 30 kg/m with weight-related comorbidities), when provided through specialist weight management services, and for a maximum duration of 2 years

The guidelines mention vitamin D, calcium, B12, and a multivitamin supplement can be considered to reduce nutrient deficiencies

Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA

Failure to do so can result in temporary grounding or certificate action to safeguard aviation safety